Jean-Pierre Garnier, Ph.D., was appointed non-executive Chairman of the board in November 2020.  Dr. Garnier is a seasoned leader with decades of experience within the global bio-pharma industry.

Most recently, Dr. Garnier was Chairman of Idorsia, a public bio-technology company based in Switzerland and listed on the Swiss Stock Exchange (SIX), which was spun off of Actelion LTD with a billion-dollar investment from Johnson & Johnson (J&J). Previous to his tenure at Idorsia, he was Chairman of Actelion Ltd., a Swiss pharmaceuticals and bio-technology company. In 2017, Actelion LTD was sold for $30 billion to J&J.

Dr. Garnier previously served as Chief Executive Officer of Pierre Fabre SA (2008 to 2010), as Chief Executive Officer and Executive Member of the Board of Directors of GlaxoSmithKline plc (2000 to 2008), and as Chief Executive Officer of SmithKline Beecham plc (2000). Before becoming CEO at SmithKline Beecham plc, he served as Chief Operating Officer and Executive Member of the Board of Directors from 1996 to 2000. 

Dr. Garnier has been a Board member of Renault S.A. (2008 to 2016), United Technologies Corporation (1997 to 2019), and Max Planck Institute (2013 to 2019).

Since 2019, Jean-Pierre Garnier is director of Carrier Global Corp. a NYSE-listed heating, air conditioning, refrigeration, fire and security solutions company. He served as Chairman of the Board of Directors of Carmat, a public (Euronext Paris - from 2018 til 2022) artificial heart company based in France. From 2016 til 2022, Dr. Garnier served as Director of the board of Radius Therapeutics, a Nasdaq-listed pharmaceutical company.

In 2006, Dr. Garnier was named as one of the top 20 Worldwide CEOs by the Best Practice Institute. He was made a Knight Commander of the British Empire. Finally, he was most recently promoted from Chevalier to Officier de la Légion d’Honneur of France.

Dr. Garnier holds an MS in pharmaceutical science and a Ph.D. in pharmacology from the Louis Pasteur University of Strasbourg, France. He subsequently earned his MBA at Stanford University, California, as a Fulbright Scholar.

Dr Garnier is considered an independent director in accordance with the criteria of the Nasdaq rules and the Middlenext Code.

Marc became CEO of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. He had previously served as an Executive Director and AstraZeneca’s Chief Financial Officer from November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GSK, has given him extensive industry experience. He is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, Global Product and Portfolio Strategy from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC Paris and a Bachelor of Law degree from Paris University. Marc is a member of the Board of JCR Pharmaceuticals.

Tyrell J. Rivers, Ph.D., Dr. Rivers has been an Executive Director within AstraZeneca’s Corporate Development & Ventures group since 2014. From 2009 to 2014, Dr. Rivers was at MedImmune Ventures specializing in biotechnology investing. Dr. Rivers also serves as a member of the board of directors of ADC Therapeutics SA, Cerapedics, Inc., and Quell Therapeutics, Ltd. Dr. Rivers holds a B.S. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering from the University of Texas at Austin and an M.B.A. from New York University Stern School of Business.

André Choulika, Ph.D., is one of the founders of Cellectis and served as Chief Executive Officer since the company's inception in 1999. He served as Chairman of the Board of Directors from 2011 to November 2020 and President of Calyxt from August 2010 to July 2020. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +). In June 2019, Dr. Choulika was appointed to the Board of Directors of the Institut Pasteur.

André Choulika was awarded Chevalier of the Légion d'Honneur in France.

Laurent Arthaud has served as a member of Cellectis’ Board of Directors since 2011. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies for Bpifrance Investissement (formerly CDC Enterprises, a subsidiary of Caisse des Dépôts) since 2012. From 2006 to 2012, Mr. Arthaud held the position of Deputy CEO at CDC Entreprises. Mr. Arthaud is a graduate of the École Polytechnique and the l’École Nationale de Statistique et d’Administration Économique.

Mr. Arthaud has been a member of the Board of Directors of Sparing Vision SAS since 2016, Kurma Life Sciences since 2012, Aledia since 2017, Ribogenics, Inc. since 2018, Enyo Pharma since 2019 and ArgoBio since 2021. 
Mr. Arthaud was also a member of Adocia's Board of Directors from 2009 to 2022.

Pierre Bastid has served as a member of Cellectis’ Board of Directors since 2011. Mr. Bastid has 25 years experience in turning around, developing and running technology businesses in Asia, Europe and the U.S. In particular, he initiated and completed the most successful European management buy out of the last 15 years: he bought the Power Conversion Division of French Engineering Alstom for $100M in 2005 and sold it to General Electric in 2011 for $3B.
In addition to his involvement with Cellectis, Mr. Bastid is currently serving on the Board for Pharnext and Carmat. Mr. Bastid also advises a number of Investment and Private Equity firms.

Mr Bastid is considered an Independent Director according to the Nasdaq rules.

Dr. Bergstrom, currently serves as Executive Vice President, Head of Research and Development at Relay Therapeutics, Inc., a clinical-stage precision medicines company. He brings with him over 15 years of experience in the biopharmaceutical and medical industries.

Prior to his tenure at Relay Therapeutics, Dr. Bergstrom was Chief Medical Officer at Mersana Therapeutics, where he led the advancement of two products based on Mersana’s proprietary antibody-drug conjugate platform through non-clinical development and into Phase 1 clinical trials. Prior to Mersana, he was Global Head of Translational and Experimental Medicine at Sanofi Oncology. At Sanofi, Dr. Bergstrom held roles of increasing responsibility at Merck Research Laboratories, culminating in his role as Oncology Franchise Lead, Experimental Medicine. Dr. Bergstrom was also recently appointed to the Board of Directors at Fusion Pharmaceuticals.

Mr Bergstrom is currently a member of the Board of Directors of Fusion Pharmaceuticals.

Dr. Bergstrom holds an M.D. from the University of Washington, Seattle, and a Ph.D. from the Fred Hutchinson Cancer Research Center, where he also completed his post-doctoral training. He was a resident in clinical pathology at the University of Washington.

Mr Bergstrom is considered an independent director in accordance with the Nasdaq rules and the Middlenext Code.

Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc. Prior to her tenure at NextVivo, Dr. Chartier was Vice President of Research at Iovance Biotherapeutics, Inc. where she led the development of next generation of tumor-infiltrating lymphocytes (TIL) therapies through research to early-stage clinical trials.

Prior to this, she spent 12 years at OncoMed Pharmaceuticals, where she served as Senior Director of Target Validation and led multiple antibody therapeutics project teams through Research and Development to IND filing. She also worked at Shering (US Berlex) and Transgene (France), where she focused on gene therapy.

Dr. Chartier obtained her Ph.D. in molecular biology from the Université Louis Pasteur in Strasbourg, France and pursued a post-doctoral training at Harvard Medical School.

Mrs. Chartier is considered an independent director under the criteria of the Nasdaq rules and the Middlenext Code.

Rainer Boehm spent 29 years at Novartis, working locally, regionally and globally in various Senior Management roles, after building his career in Marketing & Sales and Medical Affairs. He led all emerging markets regions as well as the United States and Canada, either for Oncology or the Pharmaceuticals division. His most recent assignments were Chief Commercial and Medical Affairs Officer globally for Novartis Pharma, as well as ad interim CEO and Division Head Pharma. Rainer launched and oversaw the commercialization of many brands during his career, amongst them Femara, Zometa and Glivec, as well as Cosentyx and Entresto. Rainer Boehm is currently a member of the Board of Directors of BioCopy AG (since 2018), Berlin Cures AG (since 2022) and Omega Therapeutics (since 2022). Rainer has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.

Mr Boehm is considered an independent director under the criteria of the Nasdaq rules and the Middlenext Code.

Axel-Sven Malkomes served as Chief Financial Officer & Chief Business Officer at Medigene AG, a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, until March 31st, 2022. He brings with him over 25 years of experience in the healthcare sector.  

Previous to his tenure at Medigene, Mr. Malkomes served as Vice Chairman & Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Prior to joining Barclays, he was Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale.    

On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK listed private equity firm 3i plc. as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as Head of Strategic Planning as well as Head of Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business. 

During his international management career, Mr. Malkomes gained extensive knowledge of the pharmaceutical industry. 

Mr. Malkomes is considered an independent director under the criteria of the Nasdaq rules and the Middlenext Code.

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr. Sourdive combines a strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016 and as Executive Vice President, Technical Operations until July, 2019. In addition to his role at Cellectis, Dr. Sourdive has also served on the board of directors of the Mediterranean Institute for Life Sciences. David Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

Professor Catherine Bollard, MBChB, MD, FRACP, FRCPA, is Director of the Center for Cancer and Immunology Research and Director of the Program for Cell Enhancements and Technologies for Immunotherapy at the Children’s Research Institute, Children’s National Health System and The George Washington University. A distinguished hematologist and immunotherapist, Dr. Bollard’s research interests focus on areas that include developing cell and gene therapies for patients with cancer and underlying immune deficiencies.

Stephan Grupp, MD PhD, is the Chief of the Cellular Therapy and Transplant Section, Director of the Cancer Immunotherapy Program, and Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the University of Pennsylvania. A bone marrow transplant physician, he is a member of the Division of Oncology and the Medical Director of the Cell and Gene Therapy Lab. Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology.He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary area of clinical research is the use of CAR T and other engineered cell therapies in relapsed pediatric cancers. He led all of the pediatric ALL trials of CTL019 (now approved as Kymriah), including the largest and most successful engineered T cell therapy clinical trial conducted to date, as well as the global registration trial for CTL019. As a result of this work, he presented the Clinical Perspective at the July 2018 FDA ODAC meeting, at which reviewers voted 10-0 for recommendation of approval for Kymriah in pediatric ALL. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Dr. Grupp is a reviewer for several journals and the author of over 180 peer-reviewed journal articles, as well as numerous abstracts and book chapters.

Axel-Sven Malkomes served as Chief Financial Officer & Chief Business Officer at Medigene AG, a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, until March 31st, 2022. He brings with him over 25 years of experience in the healthcare sector.  

Previous to his tenure at Medigene, Mr. Malkomes served as Vice Chairman & Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Prior to joining Barclays, he was Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale.    

On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK listed private equity firm 3i plc. as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as Head of Strategic Planning as well as Head of Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business. 

During his international management career, Mr. Malkomes gained extensive knowledge of the pharmaceutical industry. 

Mr. Malkomes is considered an independent director under the criteria of the Nasdaq rules and the Middlenext Code.

Professor Ola Landgren, MD, is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center New York and Professor of Medicine at Weill Cornell Medical College. He is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring. He has a strong interest in the development of early-treatment clinical trials, targeting high-risk smoldering myeloma. He develops new strategies (including cell-based, molecular-based and imaging-based) and implements advanced MRD testing in clinical trials at MSK.

Doctor Marcela V. Maus, MD, PhD, is Director of Cellular Immunotherapy at the Massachusetts General Hospital in Boston and Assistant Professor at Harvard Medical School. She is a board-certified hematologist-oncologist with extensive research experience in all aspects of pre-clinical and clinical design and use of cell therapies and gene-modified T-cells for cancer. Dr Maus completed undergraduate studies at MIT and her MD and PhD at Penn. As a graduate student, she worked with Dr. Carl June on the biology of human T cell activation. She completed residency training in internal medicine at the University of Pennsylvania Health System, and completed fellowship training in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center. Her research focuses on the pre-clinical development and clinical translation of engineered T cell therapies.

Professor Ghulam J Mufti is one of the founding members of The MDS Foundation Inc. He is also the head of the department of hematological medicine at Guy’s, King’s and St Thomas’s hospitals, King’s College London, with a team of 13 professors, 6 senior lecturers/lecturers and approximately 100+ research staff. In addition, Professor Mufti is a non-executive director of King’s College Hospital NHS Foundation Trust and was awarded an Officer of the Order of British Empire (OBE) in the Queen’s New Year honors list in January 2017.

Professor Ghulam Mufti has extensive clinical and research expertise in leukemias, lymphomas and in particular myelodysplastic syndromes, for which he is internationally renowned. His particular area of research has focused on molecular aberrations in MDS/AML and the identification of novel therapies that include gene and cell based therapies. He has published 500+ papers (H-Index: 78, I-Index: 11) and chapters in scientific journals and textbooks on leukemias /MDS and bone marrow failure syndromes. 

Professor Dietger Niederwieser, MD, is Professor of Medicine, Head of the Division of Hematology and Medical Oncology at University of Leipzig and University Hospital. His therapeutic areas of expertise include Clinical Immunology, Hematology and Oncology, and his research is focused on stem cell transplantation, cell therapies and gene therapies. He has extensive experience in health economics, outcomes research, clinical development of innovative drugs and clinical studies.

Professor Rai, an internationally renowned leukemia researcher and hematologist, brings extensive knowledge and experience from his 50-year career spanning groundbreaking clinical leukemia research. He is the Joel Finkelstein Cancer Foundation Professor of Medicine at the Hofstra North Shore-LIJ School of Medicine, where he is also Professor of Molecular Medicine. He is currently Chief of the Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program at Northwell Cancer Institute and an Investigator at The Feinstein Institute for Medical Research.